A randomized clinical trial compared the rate of detection of AF with use of an implantable loop recorder for 12 months vs. use of an external loop recorder for 30 days in patients with recent ischemic stroke without known AF.

The predictive performance of six risk scores for ischemic stroke in patients with AF and CKD were validated. The Modified CHADS2 score showed good performance for discrimination and calibration in all kidney function categories.

ACC 2021 The ADAPTABLE trial demonstrated similar effectiveness with 81 mg vs. 325 mg of daily aspirin in patients with established ASCVD. Also, major bleeding events were comparable between patients taking low-dose or regular-strength aspirin.

This meta-analysis showed that patients without an indication for oral anticoagulation experienced fewer combined thromboembolic and bleeding events, and no increase in thromboembolic events after TAVI when treated with aspirin compared to those receiving DAPT.

This study described the clinical features of 23 patients who after receiving the first dose of ChAdOx1 nCoV-19 vaccine developed atypical platelet factor 4 (PF4)-dependent thrombosis and/or thrombocytopenia that resembles heparin-induced thrombocytopenia.

This study validated six risk scores for ischemic stroke in patients with AF across the spectrum of kidney function. The Modified CHADS2 score showed most consistent predictive performance in all kidney function categories.

Lower dose edoxaban regimen decreased the net clinical outcome of major bleeding, stroke/systemic embolism, and death compared to higher dose edoxaban regimen in patients with AF.

The prospective BIOSIGNAL cohort study showed that elevated Lp(a) was independently associated with LAA stroke etiology and risk of recurrent AIS or TIA in patients <60 years.

ICS 2021 The Neuro-AFib study analyzed the frequency and outcomes of hemorrhagic strokes (HS) and ischemic strokes (IS) in patients with AF and showed that HS were related to increased mortality and disability as compared to IS in AF.

ISC 2021 Using data of the AHA COVID-19 CVD Registry, risk of ischemic stroke was 0.75% in patients hospitalized with COVID-19, which is lower than previously reported.

ISC 2021 This analysis of the Cardiovascular Health Study showed that silent MI, defined as ECG evidence of MI without clinical recognition of an event, was significantly associated with incident stroke.

ISC 2021 Prespecified and post hoc analyses from REDUCE-IT showed that icosapent ethyl reduced first and total stroke, and first and total ischemic stroke compared to placebo in CVD patients or patients with diabetes and one CV risk factor.